Tuesday, July 14, 2026

11:15 AM - 1:15 PM

---

Details

The RAAS is a well-documented system regulating cardiovascular/fluid balance via the angiotensin II-angiotensin II type 1 receptor (AT1R) axis. Although multiple RAAS-interfering drugs exist, even today new targets are being introduced; e.g. angiotensinogen suppression with liver-targeted siRNA and aldosterone synthase inhibitors, together with angiotensin II being repurposed for septic shock (Presentations 1-3). Thereafter, novel RAAS components acting via non-AT1R mechanisms, representing non-classical counterregulatory RAAS axes, will be discussed (Presentations 4-6): 1- Angiotensinogen suppression 2- Targeting Aldosterone inhibition by different mechanisms 3- RAAS as a biomarker and effector for septic shock 4- Angiotensin peptides: metabolites or orchestral players 5- Angiotensin receptors: signaling and receptor interactions 6- Angiotensin IV- insulin regulated aminopeptidase nexus This Workshop aptly demonstrates novel and innovative drug targets (4-6) as well as new insights into classical RAAS paradigms (1-3). As such, this Workshop will be of broad interest to WCP community, delivered by experts in their fields.

---

Session chair